A novel Bayesian fine-mapping model using a continuous global-local shrinkage prior with applications in prostate cancer analysis

Xiang Li; Pak Chung Sham; Yan Dora Zhang

doi:10.1101/2023.08.04.23293456

Abstract

The aim of fine-mapping is to identify genetic variants causally contributing to complex traits or diseases. Existing fine-mapping methods employ discrete Bayesian mixture priors and depend on a pre-specified maximum number of causal variants which may lead to sub-optimal solutions. In this work, we propose a novel fine-mapping method called h2-D2, utilizing a continuous global-local shrinkage prior. We also present an approach to define credible sets of causal variants in continuous prior settings. Simulation studies demonstrate that h2-D2 outperforms the state-of-art fine-mapping methods such as SuSiE and FINEMAP in accurately identifying causal variants and estimating their effect sizes. We further applied h2-D2 to prostate cancer analysis and discovered some previously unknown causal variants. In addition, we inferred 385 target genes associated with the detected causal variants and several pathways that were significantly over-represented by these genes, shedding light on their potential roles in prostate cancer development and progression.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded, in part, by the Hong Kong Research Grants Council (RGC) Early Career Scheme 2021/22 (project number 27305221).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used UK Biobank data under Application Number 58942 that were originally located at: https://www.ukbiobank.ac.uk/ The study used openly available 1000 Genomes on GRCh38 data that were originally located at: https://www.internationalgenome.org The study used openly available prostate cancer meta-analysis summary data that were originally located at: http://practical.icr.ac.uk/blog/?page_id=8164

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes